(IN BRIEF) EQT Life Sciences is investing USD 17.5 million in Vaderis Therapeutics as part of the Swiss biotechnology company’s USD 152 million Series B financing. The funding will support the global Phase 3 HEROIC study of engasertib, Vaderis’ lead … Read the full press release
Posted in Business, Financial, Healthcare, Investment, Pharma & Biotech, Science, Sweden, Switzerland, Technology
Tagged Azmi Nabulsi, biotechnology investment, Christoph Broja, chronic anemia, clinical-stage biotechnology, Droia, engasertib, epistaxis, EQT Life Sciences, EQT Life Sciences Backs Vaderis Therapeutics’ Phase 3 Development of Engasertib, EQT Life Sciences Invests USD 17.5 Million in Vaderis Therapeutics Series B, global Phase 3 trial, Goldman Sachs Alternatives, hereditary hemorrhagic telangiectasia, HEROIC study, HHT, inherited blood vessel disorder, Kalehua Capital, late-stage clinical development, long-term extension data, Medicxi, no approved therapies, Omega Funds, Patient Advocacy, Perceptive Advisors, phase 3 study, pivotal development, proof-of-concept data, rare disease therapy, rare genetic vascular disease, rare vascular disease, regulatory approval, Series B financing, severe nosebleeds, Swiss biotechnology company, targeted therapies, TCGX, The New England Journal of Medicine, USD 152 million financing, USD 17.5 million investment, Vaderis Therapeutics, Vaderis Therapeutics Secures USD 152 Million Series B to Advance HHT Therapy, vascular abnormalities
(IN BRIEF) Sanofi has received approval from Japan’s Ministry of Health, Labour and Welfare for the subcutaneous formulation of Sarclisa, or isatuximab, in combination with approved standard-of-care regimens for multiple myeloma. The approval covers use with pomalidomide and dexamethasone, or … Read the full press release
Posted in European Union, France, Government, Healthcare, Pharma & Biotech, Science, Security & Safety, Technology
Tagged anemia, anti-CD38 monoclonal antibody, anticancer treatment, bortezomib, cancer treatment, carfilzomib, CirCLIQ on-body injector, COVID-19, dexamethasone, Enable Injections, enFuse platform, European Union, hematologic malignancy, immunological therapies, infusion reactions, injection-site reactions, IRAKLIA phase 3 study, isatuximab, Japan, Japan Approval of Sarclisa Subcutaneous Builds on Phase 3 IRAKLIA Study Results, Japan Approves Sanofi’s Sarclisa Subcutaneous for Newly Diagnosed and Relapsed Multiple Myeloma, Japan Ministry of Health Labour and Welfare, Kd, lenalidomide, manual subcutaneous injection, Multiple Myeloma, NCT05405166, NDMM, neutropenia, newly diagnosed multiple myeloma, non-inferior efficacy, objective response rate, Olivier Nataf, on-body injector, oncology, ORR, Pd, pharmacokinetics, pneumonia, pomalidomide, R/R MM, relapsed or refractory multiple myeloma, Sanofi, Sanofi’s Sarclisa Subcutaneous Approval in Japan Expands Treatment Delivery Options for Multiple Myeloma Patients, Sarclisa, standard-of-care regimens, Subcutaneous formulation, targeted therapies, thrombocytopenia, United States, upper respiratory tract infection, VRd
(IN BRIEF) Evotec SE has reached key milestones in its molecular glue degrader collaboration with Bristol Myers Squibb, earning $75 million in performance- and program-based payments. The partnership, built on Evotec’s AI-driven drug discovery platforms and BMS’s CELMoD™ technology, continues … Read the full press release
Posted in Business, Financial, Germany, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology
Tagged AI drug discovery, biotech partnerships, Bristol-Myers Squibb, CELMoD, Cord Dohrmann, E3 ligase, Evotec, first-in-class, milestone payments, molecular glue degraders, oncology, PanOmics, partnership, pharmaceutical R&D, protein degradation, targeted therapies, unmet medical needs
(IN BRIEF) Scientists at the Institute of Cancer Research in London have developed an innovative algorithm named SYLVER, which analyzes data from over 9,300 patients to identify synthetic lethal gene pairs that cancer cells depend on for survival. Unlike previous … Read the full press release
Posted in Business, Education, Financial, Healthcare, Industrial, Investment, Management, News, Science, Technology, United Kingdom
Tagged 300 patients, 9, algorithm, backup genes, BRCA mutations, Breast Cancer Now, buffering mechanism, Cancer, Cancer Genome Atlas, Cancer Research UK, Dr Hattie Brooks, Dr Simon Vincent, Dr Syed Haider, inhibitor drugs, Institute of Cancer Research, London, NIHR Biomedical Research Centre, Professor Chris Lord, protein targets, Royal Marsden NHS Foundation Trust, SYLVER, synthetic lethality, targeted therapies, tumour-suppressor genes, Walk the Walk
(IN BRIEF) On World Cancer Day, Servier reaffirms its commitment to the fight against cancer by focusing on oncology as a central part of its Research & Development efforts. The company emphasizes the importance of understanding the personal experiences of … Read the full press release
Posted in Business, Financial, France, Healthcare, Industrial, Investment, Management, News, Science, Technology
Tagged brain tumors, cancer burden, Cancer Prevention, cancer research, cancer treatments, cancer-related deaths, digestive cancers, Early Detection, educational resources, global rankings, hematological cancers, immuno-oncology, oncology, patient experience, patient experiences, PatientView, personalized care, rare cancers, research development, screening, Servier, SHAPE program, targeted therapies, therapeutic solutions, U.S., UICC, Union for International Cancer Control, United by Unique, World Cancer Day, World Cancer Day campaign
(IN BRIEF) GSK and the University of Oxford have launched the GSK-Oxford Cancer Immuno-Prevention Programme, a new research initiative focused on cancer prevention through vaccination. GSK is investing up to £50 million to explore how precancerous cells develop into cancer, … Read the full press release
Posted in Education, Healthcare, Pharma & Biotech, Science, Technology, United Kingdom
Tagged Cancer Prevention, cancer vaccines, clinical trials, early-stage cancer, GSK, GSK-Oxford Cancer Immuno-Prevention Programme, GSK’s immune system expertise, immune system, immuno-oncology, Institute of Molecular and Computational Medicine, neoantigen sequencing, neoantigens, Peter Kyle, precancer biology, Professor Irene Tracey, targeted therapies, Tony Wood, translational research, tumor-specific proteins, University of Oxford, vaccination, vaccinology
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?